Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in Illinois: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 32 | 902 | 30% |
| 2020 | 25 | 716 | 33% |
| 2021 | 22 | 720 | 37% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in Illinois; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 165 | 12,036+1%/yr | +1%/yr | 8.40.9× | 66% | 13,800 in 2030+2.3%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in Illinois · Every state · Compare with Ohio
| 2024 |
| 692 |
| 47% |
| 2025 est. | ≈ 790 | – |
| 2026 est. | ≈ 800 | – |
| 2022 | 22 | 630 | 42% |
| 2023 | 23 | 636 | 45% |
| 2024 | 20 | 692 | 47% |
| 2025 from claims | – | 789 638–927 | 48% |
| 2026 forecast | – | 800 627–1,005 | 48% |
| 2027 forecast | – | 804 596–1,063 | 48% |
| 2028 forecast | – | 808 572–1,116 | 49% |
| 2029 forecast | – | 812 552–1,165 | 50% |
| 2030 forecast | – | 816 535–1,211 | 50% |
In 2025, 3% inpatient hospital, 51% hospital outpatient, 47% surgery center. The share outside the hospital has moved +13 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~800 | ~22 | ~390 | ~380 |
| 2027 · ~800 | ~22 | ~390 | ~390 |
| 2028 · ~810 | ~22 | ~390 | ~390 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 49% (47% in 2025), hospital outpatient about 48% (51% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| −4.8%/yr |
| 0.9 |
| 75% |
| 780 in 2030+1.7%/yr |
| Missouri | 21 | 634−4.8%/yr | −4.8%/yr | 0.9 | 41% | 660 in 2030+0.5%/yr |
| Michigan | 13 | 535−8.6%/yr | −8.6%/yr | 0.6 | 51% | 480 in 2030−1.9%/yr |
| Kansas | 19 | 505−4.3%/yr | −4.3%/yr | 1.2 | 38% | 660 in 2030+4.7%/yr |
| Minnesota | 12 | 445−2.2%/yr | −2.2%/yr | 0.9 | 87% | 660 in 2030+6.9%/yr |
| Wisconsin | 10 | 363−4.6%/yr | −4.6%/yr | 0.6 | 50% | 420 in 2030+2.4%/yr |
| Nebraska | 5 | 200−5.3%/yr | −5.3%/yr | 0.7 | 65% | 270 in 2030+5.4%/yr |
| Iowa | 3 | 125−16%/yr | −16%/yr | 0.3 | 65% | 110 in 2030−1.9%/yr |
| South Dakota | 2 | 110−11%/yr | −11%/yr | 0.8 | 23% | 130 in 2030+3.2%/yr |
| 14 |
| 1,015+11%/yr |
| +11%/yr |
| 0.70.6× |
| 41% |
| 2,110 in 2030+13%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 30% of company spending on these surgeons in 2025, level with 2024.
In 2025, 11 companies reported engagement with Illinois’s surgeons worth $655K in consulting, speaking, meals and travel tied to these products, about $33K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.